BridgeBio Pharma, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Frank P. McCormick, Ph.D.

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Frank P. McCormick, Ph.D.”): 153,020,532 for, 8,086,338 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 61,342,754 for, 3,145,553 withheld, 86,559 abstained, 204 not voted.

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Hannah A. Valantine, M.D.

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: Hannah A. Valantine, M.D.”): 129,081,930 for, 32,024,940 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 52,311,370 for, 11,514,685 withheld, 748,812 abstained, 204 not voted.

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

Description as filed by funds: To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: James C. Momtazee

BridgeBio Pharma, Inc.’s own tally for this item (“Elect Director: James C. Momtazee”): 156,790,852 for, 4,316,018 withheld, per its Form 8-K filed June 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 62,620,104 for, 1,887,070 withheld, 67,692 abstained, 204 not voted.

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.

BridgeBio Pharma, Inc.’s own tally for this item (“5. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 132,402,786 for, 27,350,537 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 131 asset managers below reported 54,945,059 for, 9,610,141 against, 272,209 abstained, 204 not voted.

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

BridgeBio Pharma, Inc.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 152,949,577 for, 6,938,080 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 122 managers: 59,857,717 for, 4,534,345 against, 40,813 abstained, 204 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 370 managers: 117,791,121 for, 5,956,173 against, 2,709 not voted, 664,940 mixed, 37,672 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 119 managers: 167,160 for, 40,809 abstained, 204 not voted, 63,814,167 1 year, 247,872 3 year, 29,693 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 353 managers: 5,954,576 for, 1,327 not voted, 109,465,615 1 year, 5,089,843 2 year, 1,125,454 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

BridgeBio Pharma, Inc.’s own tally for this item (“4. Ratification of Appointment of Independent Registered Accounting Firm”): 175,420,234 for, 203,310 against — passed, per its Form 8-K filed June 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 64,174,978 for, 4,275 against, 40,809 abstained, 204 not voted.

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.